The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and hematologic toxicity of carboplatin and talazoparib combination therapy in BRCA mutated patients.
 
Mallika Sachdev Dhawan
No Relationships to Disclose
 
Rahul Raj Aggarwal
No Relationships to Disclose
 
Imke Bartelink
No Relationships to Disclose
 
Jim Leng
No Relationships to Disclose
 
Scott Thomas
No Relationships to Disclose
 
Nela Pawlowska
No Relationships to Disclose
 
Laurie Stevenson
No Relationships to Disclose
 
Amy Jo Chien
No Relationships to Disclose
 
Robin Kate Kelley
Consulting or Advisory Role - Lilly
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Tekmira (Inst)
 
Julia Clennell
No Relationships to Disclose
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)